NEW YORK, Feb. 20, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Egalet Corporation securities (NASDAQ:EGLT) from December 15, 2015 through January 9, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Egalet investors under the federal securities laws.
To join the Egalet class action, go to http://rosenlegal.com/cases-1046.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Egalet’s business, operations, and prospects, including that: (1) Egalet misrepresented ARYMO ER’s oral abuse-deterrent profile, (2) Egalet falsely or misleadingly overstated ARYMO ER’s chances to receive the oral abuse-deterrent labeling, (3) the NDA for ARYMO ER lacked sufficient data to support the oral-labeling claims, (4) the label was likely not to include the oral abuse-deterrent claims, and (5) as a result, Egalet’s statements, as well as Defendants’ statements about Egalet’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1046.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bill Ackman Eyes New Fund to Bet Against Market Complacency 



